Startup profile · funding coverage
Clair Health funding, valuation and investors
Women's-health wearable interpreting hormone-related physiological signals; Speedrun SR006, $11M seed.
Verified company research · funding, investors and latest developments
Keep track of Clair Health
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed
$11M · June 17, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$11M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · Mountain View, California, United States
Investors in latest funding
Lead: Khosla Ventures
Other: a16z Speedrun
Overview
Clair Health is developing a wrist-worn consumer wellness device that interprets physiological signals associated with menstrual and hormonal patterns. It markets cycle, sleep, recovery and activity insights using multiple sensors and machine-learning models. The team, led by Jenny Duan and Abhinav Agarwal, participated in Speedrun SR006.
In June 2026 Fortune reported an $11M seed led by Khosla Ventures with participation from a16z Speedrun and additional investors. The company reported roughly 25,000 people on its waitlist and a sold-out presale at that time; these are not evidence of long-term consumer retention or delivered devices.
Importantly, the product estimates hormonal trends from indirect signals: it is not established here that it directly measures blood hormones or has completed the studies necessary for medical diagnosis. Clair says further validation studies are underway, and prospective consumers should not interpret the gadget as a substitute for clinical tests.
Why Clair Health is interesting
Clair was featured by Fortune after an $11M seed and a reported 25,000-person waitlist. It is also a case where health-device claims require heightened evidence scrutiny: sensor-model inference is not equivalent to direct clinically validated hormone measurement.
Product & use cases
Wearable sensors and companion analytics intended to interpret cycle-related physiological patterns and wellness measures.
- Consumers exploring menstrual and recovery trends from wearable signals
- Researchers studying noninvasive physiological proxies for hormonal cycles
- Investors tracking women's-health hardware manufacturing and validation risk
Funding history (newest first)
Seed
2026-06-17 $11M- Khosla Ventures (lead)
- a16z Speedrun (participant)
Source: Read source · fortune.com
Competitive landscape
Edge: Potential differentiated female-focused models, but evidence for accuracy, regulatory claims and reproducibility is essential.
-
Oura adjacent
Sleep and cycle-related physiological tracking
-
Whoop adjacent
Recovery and activity tracking
-
Clinical hormone testing alternative
Direct measurements for decisions requiring medical certainty
Notable stories
- Official cohort and company disclosures: https://speedrun.a16z.com/companies/clair-health
- Independent funding and waitlist reporting: https://www.fortune.com/2026/06/17/clair-khosla-anne-wojcicki-wearble-oura-whoop-hormone-women-health/
- Company describes planned validation: https://www.wearclair.com/
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Clair Health
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.